OTLK (Outlook Therapeutics) LT-Debt-to-Total-Asset: 0.52 (As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
16 GF Score
Price $1.45
! 5 Warning Signs
View Full Analysis

What is Outlook Therapeutics LT-Debt-to-Total-Asset?

Outlook Therapeutics OTLK -1.69% 16 LT-Debt-to-Total-Asset is 0.52 as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 16/100. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Outlook Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.52.

Outlook Therapeutics's long-term debt to total assets ratio declined from Mar. 2025 (1.12) to Mar. 2026 (0.52). It may suggest that Outlook Therapeutics is progressively becoming less dependent on debt to grow their business.

Outlook Therapeutics  (NAS:OTLK) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Outlook Therapeutics LT-Debt-to-Total-Asset Related Terms

Outlook Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics LT-Debt-to-Total-Asset Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.00 0.00 0.01 0.01

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 0.92 0.01 0.01 0.52
OTLK
16GF Score
Outlook Therapeutics Inc OTLK
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics LT-Debt-to-Total-Asset Calculation

Outlook Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )/Total Assets (A: Sep. 2025 )
=0.189/18.584
=0.01

Outlook Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=11.281/21.892
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.52 mean?
Outlook Therapeutics (OTLK) has a LT-Debt-to-Total-Asset of 0.52 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' LT-Debt-to-Total-Asset too high?
Outlook Therapeutics' current LT-Debt-to-Total-Asset is 0.52. Overall, Outlook Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' LT-Debt-to-Total-Asset compare to FULC and OBIO?
Outlook Therapeutics' LT-Debt-to-Total-Asset of 0.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current LT-Debt-to-Total-Asset is 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current LT-Debt-to-Total-Asset of 0.52. The current LT-Debt-to-Total-Asset is 0.52. Outlook Therapeutics' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current LT-Debt-to-Total-Asset is 0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
16GF Score

Get the complete analysis for OTLK

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.45
Price